2024年9月18日 · The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various...

2024年12月25日 · GLP1R (Glucagon Like Peptide 1 Receptor) is a Protein Coding gene. Diseases associated with GLP1R include Insulinoma and Hyperglycemia. Among its related pathways are Integration of energy metabolism and GPCR downstream signalling.

2024年2月29日 · GLP-1 agonists (also known as GLP-1 receptor agonists, incretin mimetics, or GLP-1 analogs) represent a class of medications used to treat T2DM and, in some cases, obesity. Examples of drugs in this class include Exenatide, Liraglutide, Dulaglutide, and Semaglutide.

Gene ID: 2740, updated on 8-Feb-2025. This gene encodes a 7-transmembrane protein that functions as a receptor for glucagon-like peptide 1 (GLP-1) hormone, which stimulates glucose-induced insulin secretion.

2022年1月10日 · Here we combine cryo-electron microscopy, molecular dynamics simulations, receptor mutagenesis and pharmacological assays, to interrogate the mechanism and consequences of GLP-1R binding to...

2020年3月9日 · GLP-1 acts on the GLP-1 receptor (GLP-1R) to lower blood glucose through enhanced glucose-dependent secretion of insulin, inhibition of glucagon secretion and slowed gastric emptying. It...

2025年2月8日 · Gene target information for GLP1R - glucagon like peptide 1 receptor (human). Find diseases associated with this biological target and compounds tested against it in bioassay experiments.

The current study functionally characterizes GLP1R with special emphasis on ligand and cellular partner binding interactions and presents a free-energy landscape as well as a functional model of the activation cycle of GLP1R.

The glucagon-like peptide-1 receptor (GLP-1R) is a significant therapeutic target for small molecule drug discovery given the therapeutic impact of peptide agonists in the diabetes sphere.

Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have recently received a lot of national attention. Repurposing GLP-1R agonists to treat some central nervous disorders is promising, but comparatively understudied. At a September 2024 …